SCHEMBL20722138

SCHEMBL20722138

O=C(CCCOC(F)(F)F)NNC(=O)C12CC(NC(=O)COc3ccc(Cl)c(F)c3)(C1)C2

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 19/20 0.56
▸ FFAR4 Q5NUL3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23358994 0.91 ATF4 (0.61) ATF4
SCHEMBL30968293 0.85 ATF4 (0.56) ATF4
SCHEMBL20973061 0.84 ATF4 (0.61) ATF4
SCHEMBL23358977 0.82 ATF4 (0.61) ATF4
SCHEMBL19555713 0.82 ATF4 (0.58) ATF4
SCHEMBL23358810 0.81 ATF4 (0.57) ATF4
SCHEMBL23381863 0.81 ATF4 (0.54) ATF4FFAR4
SCHEMBL30873689 0.81 ATF4 (0.50) ATF4
SCHEMBL29590841 0.80 ATF4 (0.61) ATF4
SCHEMBL23358914 0.79 ATF4 (0.52) ATF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. 2022-12-29 — — US disclosed
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2022-02-01 — — US disclosed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 — — US disclosed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 — — EP disclosed
WO-2019032743-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885FFAR4 4141/4885
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885FFAR4 4141/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 ATF4 183/4885FFAR4 3949/4885
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885FFAR4 4141/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E ATF4 81/4885FFAR4 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback